Welcome to this bonus episode of our MBC life podcast.We just finished the last episode of season 2, but our team is already working on season three. The premier episode will drop in September. In the meantime we hope that you will catch up on any episode you missed from the first 2 seasons. And we have a few bonus pods for you in July and August.

Our MBC life is a part of the metastatic breast cancer program at share cancer support SHARE offers many educational  sessions for people living with MBC. We are thrilled to continue to highlight them  The 2021 American Society for Clinical Oncology (ASCO) Annual Meeting was held virtually once more during the first week of June. Over the 4 days, pivotal data from trials and labs was presented from across the globe to continue to advance the oncology field and patient outcomes. A few weeks after the meeting one of our producers here on Our MBC Life Victoria Goldberg welcomed Dr Timothy Pluard  to a SHARE webinar where he discussed information from ASCO. We are pleased to bring to you that conversation and catch you up on the latest in MBC research.

OVERVIEW
Introductions. (Jump to section)

HR+ MBC

Follow up to PALOMA-3 trial(Jump to section)

Follow up to MONALEESA-3 trial (Jump to section)

Mechanisms of resistance to CDK4/6 - CDK2 (Jump to section)

SERDs (Giredestrant, Amcenestrant) (Jump to section)

SERCAs (H3B-6545) (Jump to section)

SARMs (Enobosarm) (Jump to section)

HER+ MBC

SYSUCC002 Trial  (Jump to section)

HER2 Low (trastuzumab deruxtecan, trastuzumab duocarmazine, ARX-788 and RC-48 (Jump to section)

TN MBC

The IMpassion130 Trial  (Jump to section)

Sacituzumab ASCENT (Jump to section)